“IDEXX Laboratories this morning provided strong 2018 organic growth forecasts of 9% to 11% driven by the strong growth in its Companion Animal Diagnostics segment.”,” the firm’s analyst wrote.
ZTS has been the topic of several other reports. Zacks Investment Research raised Zoetis from a hold rating to a buy rating and set a $71.00 target price on the stock in a research report on Thursday, October 12th. BidaskClub lowered Zoetis from a hold rating to a sell rating in a research report on Friday, October 6th. Goldman Sachs Group, Inc. (The) reaffirmed a neutral rating and issued a $62.00 target price on shares of Zoetis in a research report on Monday, August 7th. Piper Jaffray Companies set a $73.00 target price on Zoetis and gave the stock a buy rating in a research report on Friday, August 25th. Finally, Cowen and Company set a $70.00 target price on Zoetis and gave the stock a buy rating in a research report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $65.76.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.03. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the company posted $0.52 EPS.
WARNING: “Cantor Fitzgerald Analysts Give Zoetis Inc. (ZTS) a $75.00 Price Target” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/03/cantor-fitzgerald-analysts-give-zoetis-inc-zts-a-75-00-price-target.html.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of Infinity. Zoetis’s dividend payout ratio is presently 23.73%.
Several institutional investors have recently made changes to their positions in the company. Sii Investments Inc. WI grew its stake in shares of Zoetis by 0.3% during the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock valued at $383,000 after acquiring an additional 23 shares in the last quarter. Ironwood Investment Management LLC grew its stake in shares of Zoetis by 0.7% during the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock valued at $429,000 after acquiring an additional 48 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in shares of Zoetis by 1.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock valued at $262,000 after acquiring an additional 55 shares in the last quarter. Wilbanks Smith & Thomas Asset Management LLC grew its stake in shares of Zoetis by 1.8% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock valued at $354,000 after acquiring an additional 98 shares in the last quarter. Finally, First Manhattan Co. grew its stake in shares of Zoetis by 1.1% during the second quarter. First Manhattan Co. now owns 9,099 shares of the company’s stock valued at $567,000 after acquiring an additional 99 shares in the last quarter. Institutional investors own 93.04% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.